Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 9/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | INSR | P06213 | 6/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469134 | 0.77 | ITK (0.60) | ITKINSR | |
| SCHEMBL6469077 | 0.76 | ITK (0.50) | ITKINSRBACE1 | |
| SCHEMBL6469297 | 0.70 | BACE1 (0.48) | ITKINSRBACE1 | |
| SCHEMBL5461909 | 0.69 | CXCR4 (0.66) | KDM4ETLR8POLB | |
| SCHEMBL6470376 | 0.68 | ITK (0.65) | ITKINSRBACE1 | |
| SCHEMBL6023566 | 0.68 | KDM4E (0.39) | KDM4ETLR8 | |
| SCHEMBL5576415 | 0.68 | ITK (0.69) | ITKINSR | |
| SCHEMBL19021874 | 0.66 | USP2 (0.80) | KDM4EUSP2POLBCNR1CNR2 | |
| SCHEMBL30885089 | 0.65 | PARP1 (0.55) | PARP1CNR1CNR2ALDH1A1 | |
| SCHEMBL3920568 | 0.63 | HDAC3 (0.54) | KDM4EPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176792-A1 | Ketone substituted benzimidazole compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005070420-A1 | 1H-BENZIMIDAZOL-2-YL-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ITK INHIBITORS (INTERLEUKIN-2-INDUCIBLE T CELL KINASE) FOR THE TREATMENT OF INFLAMMATION, IMMUNOLOGICAL AND ALLERGIC DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176792-A1 | Ketone substituted benzimidazole compounds | ITK, BLK, BCKDK | ITK 1/4885KDM4E 824/4885PARP1 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.